SCA
CELG

Salient Capital Advisors’s Celgene Corp CELG Stock Holding History

Salient Capital Advisors’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,299
Closed -$299K – 211
2017
Q2 		$299K Sell
2,299
-3,774
-62% -$462K 0.01% 178
2017
Q1 		$756K Buy
6,073
+832
+16% +$99.6K 0.01% 148
2016
Q4 		$607K Buy
5,241
+2,741
+110% +$305K 0.01% 161
2016
Q3 		$261K Sell
2,500
-559
-18% -$60.5K 0.01% 215
2016
Q2 		$302K Buy
3,059
+767
+33% +$79.3K 0.01% 212
2016
Q1 		$229K Buy
+2,292
New +$236K 0.01% 228

Other funds holding CELG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Salient Capital Advisors's CELG Position: Q3 2017 in Review

Salient Capital Advisors sold out of Celgene Corp (CELG) in Q3 2017, closing a stake of 2,299 shares — an estimated $299K sold.

Salient Capital Advisors first reported a position in CELG in Q1 2016 and held it in 6 quarters. The position peaked at $756K in Q1 2017. 1,484 funds tracked by Wall St. Rank hold CELG as of Q3 2017.

  • Salient Capital Advisors reported no remaining Celgene Corp position as of Q3 2017 after selling out during the quarter.
  • Salient Capital Advisors sold 2,299 Celgene Corp shares in Q3 2017, an estimated $299K.
  • Salient Capital Advisors first reported a position in Celgene Corp in Q1 2016 and held it in 6 quarters.
  • Salient Capital Advisors's Celgene Corp position peaked at $756K in Q1 2017.
  • 1,484 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2017.

Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.